Go Pro
→ Shocking AI prediction from the “Billionaire Whisperer' (From Chaikin Analytics) (Ad)tc pixel Free TGTX Stock Alerts

TG Therapeutics (TGTX) Financials

TG Therapeutics logo
$53.89 -1.50 (-2.71%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$53.86 -0.02 (-0.05%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for TG Therapeutics

Annual Income Statements for TG Therapeutics

This table shows TG Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -63 -78 -118 -173 -173 -279 -348 -224 13 23 447
Consolidated Net Income / (Loss)		 -63 -78 -118 -173 -173 -279 -348 -224 13 23 447
Net Income / (Loss) Continuing Operations		 -63 -78 -118 -173 -173 -279 -348 -224 13 23 447
Total Pre-Tax Income 		-63 -78 -118 -173 -173 -279 -348 -224 13 26 107
Total Operating Income		 -63 -79 -119 -174 -169 -274 -345 -218 21 42 123
Total Gross Profit		 0.15 0.15 0.15 0.15 0.15 0.15 5.90 2.79 220 291 516
Total Revenue		 0.15 0.15 0.15 0.15 0.15 0.15 6.69 2.79 234 329 616
Operating Revenue		 0.15 0.15 0.15 0.15 0.15 0.15 6.69 2.79 234 329 616
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.79 0.00 14 38 101
Operating Cost of Revenue		 - - - - 0.00 0.00 0.79 - 14 38 101
Total Operating Expenses		 63 79 119 175 169 274 351 221 199 249 392
Selling, General & Admin Expense		 16 9.89 16 15 15 108 128 95 123 154 232
Research & Development Expense		 48 69 103 159 154 166 223 125 76 94 160
Total Other Income / (Expense), net		 0.23 0.72 0.24 0.92 -3.82 -5.79 -3.33 -5.50 -7.57 -16 -16
Interest Expense		 - - 0.85 0.88 5.29 6.33 5.64 10 13 24 27
Other Income / (Expense), net		 0.06 0.39 1.08 1.80 1.47 0.54 2.31 4.70 5.04 7.69 11
Income Tax Expense		 - - - - - - 0.00 0.00 0.39 2.21 -340
Basic Earnings per Share		 ($1.38) ($1.60) ($1.91) ($2.30) ($1.96) ($2.42) ($2.63) ($1.65) $0.09 $0.16 $3.10
Weighted Average Basic Shares Outstanding		 45.65M 49.04M 62.07M 75.47M 88.37M 115.33M 132.22M 135.41M 141.96M 145.32M 144.32M
Diluted Earnings per Share		 ($1.38) ($1.60) ($1.91) ($2.30) ($1.96) ($2.42) ($2.63) ($1.65) $0.09 $0.15 $2.77
Weighted Average Diluted Shares Outstanding		 45.65M 49.04M 62.07M 75.47M 88.37M 115.33M 132.22M 135.41M 148.51M 160.34M 161.41M
Weighted Average Basic & Diluted Shares Outstanding		 45.65M 49.04M 62.07M 75.47M 88.37M 115.33M 132.22M 146.36M 154.42M 157.07M 159.69M

Quarterly Income Statements for TG Therapeutics

This table shows TG Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -14 -11 6.88 3.88 23 5.06 28 391 23 20 7.78
Consolidated Net Income / (Loss)		 -14 -11 6.88 3.88 23 5.06 28 391 23 20 7.78
Net Income / (Loss) Continuing Operations		 -14 -11 6.88 3.88 23 5.06 28 391 23 20 7.78
Total Pre-Tax Income 		-14 -11 6.55 4.27 25 5.47 31 26 45 20 10
Total Operating Income		 -12 -9.27 8.82 12 30 8.62 35 29 50 35 22
Total Gross Profit		 34 58 65 75 83 105 122 134 154 171 199
Total Revenue		 44 63 73 84 108 121 141 162 193 205 240
Operating Revenue		 44 63 73 84 108 121 141 162 193 205 240
Total Cost of Revenue		 9.77 5.44 8.30 9.34 25 16 19 28 38 34 41
Operating Cost of Revenue		 - 5.44 8.30 9.34 - 16 19 28 38 34 41
Total Operating Expenses		 47 67 56 62 53 97 87 104 104 137 177
Selling, General & Admin Expense		 31 35 39 42 39 50 56 63 63 88 82
Research & Development Expense		 17 33 18 20 24 46 32 41 41 48 95
Total Other Income / (Expense), net		 -1.54 -1.41 -2.27 -8.17 -4.50 -3.15 -3.92 -3.46 -5.40 -14 -11
Interest Expense		 2.43 2.29 3.98 11 6.93 6.76 6.72 6.72 6.53 17 17
Other Income / (Expense), net		 0.89 0.88 1.71 2.67 2.44 3.60 2.79 3.27 1.13 2.39 5.13
Income Tax Expense		 0.39 0.03 -0.33 0.39 2.12 0.41 2.73 -365 22 0.59 2.45
Basic Earnings per Share		 ($0.09) ($0.07) $0.05 $0.03 $0.15 $0.03 $0.19 $2.69 $0.19 $0.14 $0.05
Weighted Average Basic Shares Outstanding		 141.96M 146.21M 144.73M 145.10M 145.32M 146.68M 146.74M 145.42M 144.32M 144.44M 141.77M
Diluted Earnings per Share		 - ($0.07) $0.04 $0.02 - $0.03 $0.17 $2.43 $0.14 $0.12 $0.05
Weighted Average Diluted Shares Outstanding		 148.51M 146.21M 159.42M 160.71M 160.34M 162.77M 162.56M 161.00M 161.41M 160.06M 157.28M
Weighted Average Basic & Diluted Shares Outstanding		 154.42M 154.54M 154.82M 155.67M 157.07M 158.76M 158.67M 158.76M 159.69M 153.08M 153.07M

Annual Cash Flow Statements for TG Therapeutics

This table details how cash moves in and out of TG Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.65 -30 32 -14 71 441 -255 -197 -9.36 87 -101
Net Cash From Operating Activities		 -45 -63 -94 -129 -133 -215 -296 -176 -31 -41 -25
Net Cash From Continuing Operating Activities		 -45 -62 -94 -129 -133 -215 -296 -176 -31 -41 -25
Net Income / (Loss) Continuing Operations		 -63 -78 -118 -173 -173 -279 -348 -224 13 23 447
Consolidated Net Income / (Loss)		 -63 -78 -118 -173 -173 -279 -348 -224 13 23 447
Depreciation Expense		 0.02 0.06 0.08 0.09 0.10 0.16 0.28 0.30 0.21 0.07 0.06
Amortization Expense		 0.54 0.46 0.19 0.02 0.70 1.11 1.81 1.73 0.35 -4.78 -2.39
Non-Cash Adjustments To Reconcile Net Income		 16 5.33 16 17 14 83 63 45 38 48 73
Changes in Operating Assets and Liabilities, net		 2.07 11 8.44 28 25 -20 -12 0.69 -82 -107 -543
Net Cash From Investing Activities		 -25 27 -8.21 1.18 -0.72 -25 -0.33 -20 -51 -1.04 14
Net Cash From Continuing Investing Activities		 -25 27 -8.21 1.18 -0.72 -25 -0.33 -20 -51 -1.04 14
Purchase of Property, Plant & Equipment		 -0.04 -0.34 -0.00 -0.09 -0.13 -0.36 -0.40 -0.01 0.00 -0.05 -0.21
Purchase of Investments		 -49 -15 -28 -31 -30 -67 -56 -107 -147 -312 -223
Sale and/or Maturity of Investments		 24 42 20 33 29 43 56 87 96 311 238
Net Cash From Financing Activities		 69 5.02 134 114 204 680 41 -0.39 73 129 -90
Net Cash From Continuing Financing Activities		 69 5.02 134 114 204 680 41 -0.39 73 129 -90
Repayment of Debt		 - -0.01 - 0.00 -0.80 0.00 -1.02 -0.98 -0.13 -108 0.00
Repurchase of Common Equity		 - - - - - - - 0.00 0.00 -8.76 -91
Issuance of Debt		 0.10 - 0.00 0.00 30 0.00 70 0.00 25 245 0.00
Issuance of Common Equity		 - - - 0.00 - - 2.22 0.00 46 0.00 0.00
Other Financing Activities, net		 69 5.03 134 114 175 680 -30 0.58 1.53 0.91 1.51
Cash Interest Paid		 - - - - - - 3.47 5.45 8.77 18 24
Cash Income Taxes Paid		 - - - - - - - 0.00 0.00 0.50 7.88

Quarterly Cash Flow Statements for TG Therapeutics

This table details how cash moves in and out of TG Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -58 -17 7.44 113 -16 -48 -3.00 -55 5.08 363 40
Net Cash From Operating Activities		 -13 -8.21 5.54 -12 -26 -29 7.44 -23 20 -18 39
Net Cash From Continuing Operating Activities		 -13 -8.21 5.54 -12 -26 -29 7.44 -23 20 -18 39
Net Income / (Loss) Continuing Operations		 -14 -11 6.88 3.88 23 5.06 28 391 23 20 7.78
Consolidated Net Income / (Loss)		 -14 -11 6.88 3.88 23 5.06 28 391 23 20 7.78
Depreciation Expense		 0.04 0.03 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.03 0.05
Amortization Expense		 -0.84 -0.98 -1.11 -1.35 -1.34 -0.98 -0.93 -0.44 -0.03 -0.03 0.04
Non-Cash Adjustments To Reconcile Net Income		 9.46 8.92 10 17 13 15 16 19 23 28 28
Changes in Operating Assets and Liabilities, net		 -7.46 -5.47 -11 -32 -61 -48 -36 -432 -26 -66 3.78
Net Cash From Investing Activities		 -45 -9.26 1.77 -9.33 16 -13 -3.99 46 -16 -9.86 1.03
Net Cash From Continuing Investing Activities		 -45 -9.26 1.77 -9.33 16 -13 -3.99 46 -16 -9.86 1.03
Purchase of Property, Plant & Equipment		 - 0.00 - - -0.02 -0.03 -0.04 -0.08 -0.07 -0.05 -0.29
Purchase of Investments		 -68 -83 -70 -102 -58 -93 -53 -31 -46 -21 -16
Sale and/or Maturity of Investments		 24 73 71 92 74 80 49 78 30 11 18
Net Cash From Financing Activities		 -0.00 0.01 0.14 134 -6.07 -6.10 -6.44 -78 1.06 391 0.09
Net Cash From Continuing Financing Activities		 -0.00 0.01 0.14 134 -6.07 -6.10 -6.44 -78 1.06 391 0.09
Other Financing Activities, net		 - 0.01 0.14 0.20 -107 0.02 0.43 - 1.06 -254 0.09
Cash Interest Paid		 4.84 2.45 2.49 7.11 6.42 6.14 6.10 6.10 5.91 2.39 18
Cash Income Taxes Paid		 - - - - - 0.00 - 1.96 0.85 3.44 7.88

Annual Balance Sheets for TG Therapeutics

This table presents TG Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 113 55 97 84 163 626 380 194 330 578 1,063
Total Current Assets		 87 51 93 79 149 612 331 168 318 566 631
Cash & Equivalents		 55 25 57 42 113 553 299 102 93 180 79
Short-Term Investments		 22 20 28 27 28 52 16 59 125 131 63
Accounts Receivable		 - - - - - 0.00 1.39 0.00 51 129 306
Inventories, net		 - - - - - - - 0.00 40 110 126
Other Current Assets		 0.31 0.22 0.44 0.44 0.61 1.08 2.88 2.36 9.52 16 58
Plant, Property, & Equipment, net		 0.05 0.33 0.25 0.25 0.28 0.48 0.60 0.31 0.00 0.00 0.00
Total Noncurrent Assets		 27 3.59 3.82 4.33 14 13 48 25 12 11 432
Long-Term Investments		 25 - - - - 0.00 36 12 0.00 0.81 59
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - - 0.00 348
Other Noncurrent Operating Assets		 0.17 0.16 - 1.24 11 11 9.89 10 12 11 25
Total Liabilities & Shareholders' Equity		 113 55 97 84 163 626 380 194 330 578 1,063
Total Liabilities		 12 19 30 60 124 106 142 135 169 355 415
Total Current Liabilities		 11 17 28 39 84 88 65 53 54 91 154
Accounts Payable		 9.35 15 26 36 30 37 51 42 38 58 108
Current Deferred Revenue		 0.15 0.15 0.15 - - - - - 0.15 11 21
Current Employee Benefit Liabilities		 0.82 1.39 1.80 2.26 3.80 8.46 10 8.43 12 15 22
Other Current Liabilities		 - - - 0.22 51 20 2.95 2.75 2.93 5.78 3.17
Total Noncurrent Liabilities		 1.37 2.04 2.43 21 40 19 77 82 115 265 261
Long-Term Debt		 - - - 0.00 29 7.72 67 71 100 244 246
Noncurrent Deferred Revenue		 1.37 2.04 2.43 2.38 0.76 0.61 0.46 0.31 6.02 12 8.81
Other Noncurrent Operating Liabilities		 - - 0.00 18 10 10 9.85 10 9.23 8.13 7.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 102 36 67 24 39 519 237 59 161 222 648
Total Preferred & Common Equity		 102 36 67 24 39 519 237 59 161 222 648
Total Common Equity		 102 36 67 24 39 519 237 59 161 222 648
Common Stock		 260 272 422 553 740 1,500 1,566 1,586 1,713 1,761 1,830
Retained Earnings		 -158 -236 -355 -528 -701 -981 -1,329 -1,527 -1,553 -1,529 -1,082
Treasury Stock		 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -8.99 -100

Quarterly Balance Sheets for TG Therapeutics

This table presents TG Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 197 221 331 373 401 586 657 703 1,025 1,529 1,640
Total Current Assets		 185 209 319 361 389 574 645 664 600 1,087 1,146
Cash & Equivalents		 61 97 151 75 83 196 132 129 74 442 483
Short-Term Investments		 78 48 78 134 134 145 144 123 58 72 70
Accounts Receivable		 8.62 17 39 65 84 116 190 232 265 392 402
Inventories, net		 27 30 34 78 81 85 158 155 147 129 148
Other Current Assets		 4.46 11 12 8.10 7.05 33 20 25 56 51 44
Plant, Property, & Equipment, net		 0.24 0.21 0.13 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 12 12 12 13 12 12 12 39 425 442 494
Long-Term Investments		 0.00 0.00 0.00 1.32 0.95 1.13 1.91 29 49 62 64
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - 367 344 343
Other Noncurrent Operating Assets		 9.97 9.75 9.55 9.20 11 11 10 10 9.88 36 86
Total Liabilities & Shareholders' Equity		 197 221 331 373 401 586 657 703 1,025 1,529 1,640
Total Liabilities		 170 180 166 213 224 394 419 426 418 946 1,036
Total Current Liabilities		 63 73 58 100 109 125 160 172 157 187 268
Accounts Payable		 57 63 40 87 93 101 134 134 112 149 214
Current Deferred Revenue		 - - 6.90 3.37 3.37 9.09 17 24 26 17 17
Current Employee Benefit Liabilities		 3.22 6.64 8.34 3.60 6.35 10 5.14 11 15 19 35
Other Current Liabilities		 2.77 3.08 2.70 5.45 5.47 4.53 4.06 3.35 3.06 2.42 2.77
Total Noncurrent Liabilities		 107 108 109 114 115 269 259 254 261 759 767
Long-Term Debt		 97 98 99 101 103 244 245 245 245 745 745
Noncurrent Deferred Revenue		 0.27 0.23 0.19 3.24 3.74 16 6.60 1.67 8.35 6.86 15
Other Noncurrent Operating Liabilities		 10 9.81 9.52 8.96 8.70 8.42 7.86 7.59 7.31 6.60 7.14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 27 40 165 160 178 192 237 276 607 583 604
Total Preferred & Common Equity		 27 40 165 160 178 192 237 276 607 583 604
Total Common Equity		 27 40 165 160 178 192 237 276 607 583 604
Common Stock		 1,594 1,655 1,665 1,685 1,734 1,747 1,777 1,794 1,813 1,846 1,859
Retained Earnings		 -1,566 -1,614 -1,500 -1,525 -1,556 -1,553 -1,524 -1,496 -1,105 -1,062 -1,054
Treasury Stock		 -0.23 -0.23 -0.23 -0.23 -0.23 -2.38 -15 -22 -100 -200 -200

Annual Metrics And Ratios for TG Therapeutics

This table displays calculated financial ratios and metrics derived from TG Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 158,759,451.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 158,759,451.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 2.82
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -44 -55 -83 -122 -118 -192 -241 -153 20 38 514
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -117.81% 7.68% 8.21% 57.46%
Earnings before Interest and Taxes (EBIT)		 -63 -79 -118 -173 -168 -273 -342 -214 26 50 134
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -63 -78 -117 -173 -167 -272 -340 -212 26 45 132
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -42 -47 -74 -95 -90 -208 -252 -154 -67 -74 -24
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.03 -9.53 -18 -45 -73 -56 -45 -44 43 155 693
Increase / (Decrease) in Invested Capital		 -2.05 -8.51 -8.65 -27 -28 17 11 1.02 87 112 538
Book Value per Share		 $1.93 $0.66 $0.95 $0.29 $0.39 $3.95 $1.66 $0.40 $1.06 $1.43 $4.08
Tangible Book Value per Share		 $1.92 $0.64 $0.94 $0.28 $0.38 $3.94 $1.65 $0.40 $1.06 $1.43 $4.08
Total Capital		 102 36 67 24 68 549 305 130 261 467 894
Total Debt		 0.21 0.07 0.13 0.00 29 30 68 71 100 244 246
Total Long-Term Debt		 0.00 0.00 0.00 0.00 29 7.72 67 71 100 244 246
Net Debt		 -102 -45 -85 -69 -111 -576 -283 -103 -117 -67 45
Capital Expenditures (CapEx)		 0.04 0.34 0.00 0.09 0.13 0.36 0.40 0.01 0.00 0.05 0.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.67 -11 -19 -29 -76 -59 -48 -47 47 165 335
Debt-free Net Working Capital (DFNWC)		 77 34 65 40 65 546 267 115 264 476 477
Net Working Capital (NWC)		 76 34 65 40 65 524 266 115 264 476 477
Net Nonoperating Expense (NNE)		 19 23 35 51 55 88 107 71 7.34 15 66
Net Nonoperating Obligations (NNO)		 -103 -45 -85 -69 -111 -576 -283 -103 -117 -67 45
Total Depreciation and Amortization (D&A)		 0.55 0.52 0.27 0.10 0.80 1.27 2.09 2.03 0.57 -4.71 -2.33
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.38) ($1.60) ($1.91) ($2.30) ($1.96) ($2.42) ($2.63) ($1.46) $0.09 $0.16 $3.10
Adjusted Weighted Average Basic Shares Outstanding		 54.10M 56.91M 75.58M 83.87M 109.40M 140.59M 142.82M 135.41M 141.96M 145.32M 144.32M
Adjusted Diluted Earnings per Share		 ($1.38) ($1.60) ($1.91) ($2.30) ($1.96) ($2.42) ($2.63) ($1.46) $0.09 $0.15 $2.77
Adjusted Weighted Average Diluted Shares Outstanding		 54.10M 56.91M 75.58M 83.87M 109.40M 140.59M 142.82M 135.41M 148.51M 160.34M 161.41M
Adjusted Basic & Diluted Earnings per Share		 ($1.38) ($1.60) ($1.91) ($2.30) ($1.96) ($2.42) ($2.63) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 45.65M 49.04M 62.07M 75.47M 88.37M 115.33M 132.22M 146.36M 154.42M 157.07M 159.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -44 -55 -83 -122 -118 -192 -241 -153 20 38 86
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for TG Therapeutics

This table displays calculated financial ratios and metrics derived from TG Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 158,759,451.00 159,688,256.00 153,083,580.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 158,759,451.00 159,688,256.00 153,083,580.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - 0.15 0.12 0.05
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 54,183.95% 713.46% 357.05% -49.41% 146.04% 90.40% 92.13% 92.79% - 69.56% 70.27%
EBITDA Growth		 83.51% 74.14% 121.73% -88.36% 350.48% 220.45% 288.98% 134.07% - 230.52% -26.75%
EBIT Growth		 84.66% 76.94% 123.94% -87.16% 379.29% 245.71% 257.48% 116.09% - 204.15% -28.78%
NOPAT Growth		 83.90% 74.94% 129.60% -90.15% 414.12% 222.96% 243.11% 3,819.42% - 323.55% -48.12%
Net Income Growth		 81.63% 72.71% 114.45% -96.59% 261.84% 147.26% 309.75% 9,974.61% - 290.85% -72.40%
EPS Growth		 0.00% 0.00% 111.76% -97.26% 0.00% 142.86% 325.00% 12,050.00% - 300.00% -70.59%
Operating Cash Flow Growth		 44.66% 86.30% 113.18% -114.58% -94.10% -249.88% 34.32% -89.70% - 37.68% 428.01%
Free Cash Flow Firm Growth		 -73.99% -36.56% -1.84% -191.05% 12.26% -100.52% -148.04% -179.41% - -253.54% -222.63%
Invested Capital Growth		 197.19% 419.07% 1,016.85% 172.75% 259.49% 305.07% 289.31% 613.99% - 269.00% 204.08%
Revenue Q/Q Growth		 -73.48% 44.36% 15.74% 14.17% 28.98% 11.71% 16.79% 14.57% - 6.41% 17.28%
EBITDA Q/Q Growth		 -110.49% 24.67% 201.07% 45.79% 125.65% -63.77% 226.39% -12.27% - -27.97% -27.66%
EBIT Q/Q Growth		 -109.86% 27.64% 225.48% 43.43% 114.46% -62.25% 207.86% -13.30% - -27.98% -27.91%
NOPAT Q/Q Growth		 -107.61% 25.75% 242.66% 22.10% 142.86% -70.94% 298.10% 1,294.81% - 31.00% -51.24%
Net Income Q/Q Growth		 -112.65% 25.73% 164.25% -43.60% 501.31% -78.31% 457.06% 1,286.79% - -14.15% -60.66%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -50.00% 0.00% 0.00% 466.67% 1,329.41% - -14.29% -58.33%
Operating Cash Flow Q/Q Growth		 -115.78% 37.87% 167.45% -320.47% -110.09% -11.99% 125.90% -411.36% - -191.02% 319.42%
Free Cash Flow Firm Q/Q Growth		 -281.27% 24.55% 18.17% 18.64% -74.69% -72.43% -1.22% 8.35% - -0.56% 7.63%
Invested Capital Q/Q Growth		 24.90% 16.74% 23.00% 52.08% 64.62% 31.54% 18.21% 178.92% - 8.63% -2.59%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 77.79% 91.43% 88.70% 100.00% 77.13% 87.14% 86.58% 82.63% - 83.65% 82.86%
EBITDA Margin		 -28.19% -14.71% 12.85% 16.41% 28.70% 9.31% 26.01% 19.92% - 18.14% 11.19%
Operating Margin		 -28.39% -14.60% 12.00% 14.82% 27.68% 7.13% 24.69% 18.16% - 16.98% 9.02%
EBIT Margin		 -26.37% -13.22% 14.33% 18.00% 29.93% 10.12% 26.66% 20.18% - 18.14% 11.15%
Profit (Net Income) Margin		 -32.79% -16.87% 9.36% 4.63% 21.57% 4.19% 19.97% 241.73% - 9.65% 3.24%
Tax Burden Percent		 102.78% 100.27% 105.01% 90.91% 91.66% 92.54% 91.16% 1,508.72% - 97.12% 76.03%
Interest Burden Percent		 120.97% 127.27% 62.22% 28.26% 78.60% 44.73% 82.16% 79.40% - 54.77% 38.18%
Effective Tax Rate		 0.00% 0.00% -5.01% 9.09% 8.34% 7.46% 8.84% -1,408.72% - 2.88% 23.97%
Return on Invested Capital (ROIC)		 0.00% -171.19% 158.43% 55.47% 84.29% 20.07% 67.47% 380.30% - 24.16% 11.26%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -165.68% 161.35% 61.97% 88.75% 24.15% 72.20% 696.24% - 3.51% -7.38%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 135.15% -120.53% -39.63% -42.83% -8.70% -24.03% -28.75% - 0.58% -0.78%
Return on Equity (ROE)		 11.57% -36.04% 37.90% 15.84% 41.46% 11.37% 43.44% 351.55% - 24.74% 10.48%
Cash Return on Invested Capital (CROIC)		 -156.46% -36.23% 53.45% -93.24% -74.27% -76.66% -66.42% -14.08% - 3.40% 20.65%
Operating Return on Assets (OROA)		 -23.56% -13.40% 15.98% 10.40% 21.71% 7.59% 21.94% 13.32% - 11.63% 7.61%
Return on Assets (ROA)		 -29.29% -17.10% 10.44% 2.67% 15.64% 3.14% 16.43% 159.62% - 6.19% 2.21%
Return on Common Equity (ROCE)		 11.57% -36.04% 37.90% 15.84% 41.46% 11.37% 43.44% 351.55% - 24.74% 10.48%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 25.73% 53.89% -7.48% 0.00% 16.50% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.74 -6.49 9.26 11 27 7.98 32 443 26 34 16
NOPAT Margin		 -19.88% -10.22% 12.60% 13.48% 25.38% 6.60% 22.50% 273.97% - 16.49% 6.86%
Net Nonoperating Expense Percent (NNEP)		 -5.15% -5.51% -2.92% -6.50% -4.46% -4.08% -4.73% -315.94% - 20.65% 18.64%
Return On Investment Capital (ROIC_SIMPLE)		 -3.35% - - - 5.88% 1.66% 6.09% 51.97% 2.89% 2.54% 1.22%
Cost of Revenue to Revenue		 22.21% 8.57% 11.30% 0.00% 22.87% 12.86% 13.42% 17.37% - 16.35% 17.14%
SG&A Expenses to Revenue		 70.85% 54.48% 52.80% 50.03% 36.01% 41.65% 39.38% 39.19% - 43.05% 34.17%
R&D to Revenue		 39.68% 51.55% 23.90% 24.01% 22.07% 38.36% 22.52% 25.28% - 23.62% 39.67%
Operating Expenses to Revenue		 106.19% 106.03% 76.70% 85.18% 49.45% 80.01% 61.90% 64.47% - 66.67% 73.84%
Earnings before Interest and Taxes (EBIT)		 -12 -8.39 11 15 32 12 38 33 52 37 27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 -9.34 9.44 14 31 11 37 32 52 37 27
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 16.11 14.67 15.48 18.85 21.07 26.10 20.67 9.44 - 9.10 13.92
Price to Tangible Book Value (P/TBV)		 16.11 14.74 15.48 18.85 21.07 26.10 20.67 9.44 - 9.10 13.92
Price to Revenue (P/Rev)		 11.07 8.12 7.93 13.68 14.24 16.03 12.58 10.78 - 7.57 10.52
Price to Earnings (P/E)		 204.08 57.01 28.73 0.00 200.38 158.19 94.51 12.81 - 11.48 19.05
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.49% 1.75% 3.48% 0.00% 0.50% 0.63% 1.06% 7.81% - 8.71% 5.25%
Enterprise Value to Invested Capital (EV/IC)		 57.26 44.49 42.54 37.42 29.80 30.21 23.56 8.62 - 7.28 11.65
Enterprise Value to Revenue (EV/Rev)		 10.57 7.74 7.60 13.31 14.04 15.94 12.51 10.90 - 7.82 10.68
Enterprise Value to EBITDA (EV/EBITDA)		 94.07 42.24 24.87 2,406.63 102.82 94.04 61.20 52.12 - 34.71 57.74
Enterprise Value to EBIT (EV/EBIT)		 96.14 41.71 24.34 624.37 93.07 87.70 58.33 50.46 - 34.41 57.60
Enterprise Value to NOPAT (EV/NOPAT)		 123.33 46.77 25.88 0.00 120.56 109.78 72.32 11.06 - 9.69 14.41
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 110.39 38.83 0.00 0.00 0.00 0.00 0.00 - 0.00 477.69
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 79.59 0.00 0.00 0.00 0.00 0.00 - 336.81 84.92
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.62 0.63 0.58 1.27 1.10 1.03 0.89 0.40 - 1.28 1.23
Long-Term Debt to Equity		 0.62 0.63 0.58 1.27 1.10 1.03 0.89 0.40 - 1.28 1.23
Financial Leverage		 -1.01 -0.82 -0.75 -0.64 -0.48 -0.36 -0.33 -0.04 - 0.17 0.11
Leverage Ratio		 2.39 3.04 2.85 2.57 2.37 2.59 2.43 2.02 - 2.66 2.66
Compound Leverage Factor		 2.89 3.87 1.78 0.73 1.86 1.16 2.00 1.60 - 1.46 1.02
Debt to Total Capital		 38.42% 38.76% 36.61% 55.96% 52.36% 50.77% 46.99% 28.78% - 56.10% 55.24%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 38.42% 38.76% 36.61% 55.96% 52.36% 50.77% 46.99% 28.78% - 56.10% 55.24%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 61.58% 61.24% 63.39% 44.04% 47.64% 49.23% 53.01% 71.22% - 43.90% 44.76%
Debt to EBITDA		 3.82 1.91 0.97 166.77 5.44 3.74 2.64 2.21 - 4.72 5.04
Net Debt to EBITDA		 -4.47 -2.07 -1.09 -66.95 -1.50 -0.51 -0.38 0.58 - 1.07 0.87
Long-Term Debt to EBITDA		 3.82 1.91 0.97 166.77 5.44 3.74 2.64 2.21 - 4.72 5.04
Debt to NOPAT		 5.00 2.12 1.01 -690.69 6.38 4.36 3.12 0.47 - 1.32 1.26
Net Debt to NOPAT		 -5.86 -2.29 -1.14 277.25 -1.76 -0.60 -0.45 0.12 - 0.30 0.22
Long-Term Debt to NOPAT		 5.00 2.12 1.01 -690.69 6.38 4.36 3.12 0.47 - 1.32 1.26
Altman Z-Score		 4.14 2.43 3.73 3.26 5.95 7.15 6.73 7.86 - 3.64 5.16
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.92 3.62 3.58 4.59 6.25 4.02 3.86 3.82 - 5.81 4.27
Quick Ratio		 5.00 2.76 2.77 3.65 4.85 2.91 2.81 2.53 - 4.84 3.55
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -96 -73 -59 -48 -84 -146 -147 -135 -512 -515 -475
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -122,100.00% -114,860.00% 17,704.76% -28,941.25% - -35,086.27% 13,400.34%
Free Cash Flow to Firm to Interest Expense		 -39.58 -31.73 -14.94 -4.46 -12.18 -21.54 -21.94 -20.09 - -30.60 -28.68
Operating Cash Flow to Interest Expense		 -5.43 -3.59 1.39 -1.13 -3.70 -4.25 1.11 -3.44 - -1.06 2.37
Operating Cash Flow Less CapEx to Interest Expense		 -5.43 -3.59 1.39 -1.13 -3.70 -4.25 1.10 -3.46 - -1.07 2.35
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.89 1.01 1.11 0.58 0.73 0.75 0.82 0.66 - 0.64 0.68
Accounts Receivable Turnover		 0.00 7.86 6.86 3.42 3.65 3.03 2.88 2.79 - 2.41 2.53
Inventory Turnover		 0.00 0.36 0.48 0.40 0.51 0.41 0.50 0.67 - 0.83 0.93
Fixed Asset Turnover		 0.00 1,909.79 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Payable Turnover		 0.35 0.26 0.35 0.33 0.80 0.44 0.52 0.73 - 0.84 0.81
Days Sales Outstanding (DSO)		 0.00 46.43 53.21 106.86 100.00 120.49 126.66 130.76 - 151.70 144.51
Days Inventory Outstanding (DIO)		 0.00 1,023.33 752.97 917.72 712.63 884.51 728.66 542.13 - 441.00 392.58
Days Payable Outstanding (DPO)		 1,039.52 1,407.71 1,056.52 1,095.68 458.87 830.87 701.07 500.28 - 434.83 450.25
Cash Conversion Cycle (CCC)		 -1,039.52 -337.96 -250.34 -71.10 353.76 174.13 154.24 172.61 - 157.87 86.83
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 43 50 62 94 155 204 241 672 693 752 733
Invested Capital Turnover		 -374.46 16.75 12.57 4.12 3.32 3.04 3.00 1.39 - 1.46 1.64
Increase / (Decrease) in Invested Capital		 87 66 69 60 112 154 179 578 538 548 492
Enterprise Value (EV)		 2,469 2,239 2,634 3,523 4,618 6,160 5,678 5,797 - 5,474 8,539
Market Capitalization		 2,586 2,349 2,749 3,621 4,686 6,193 5,714 5,732 - 5,305 8,410
Book Value per Share		 $1.06 $1.04 $1.15 $1.24 $1.43 $1.51 $1.74 $3.83 $4.08 $3.65 $3.95
Tangible Book Value per Share		 $1.06 $1.03 $1.15 $1.24 $1.43 $1.51 $1.74 $3.83 $4.08 $3.65 $3.95
Total Capital		 261 261 280 436 467 482 521 853 894 1,328 1,349
Total Debt		 100 101 103 244 244 245 245 245 246 745 745
Total Long-Term Debt		 100 101 103 244 244 245 245 245 246 745 745
Net Debt		 -117 -110 -116 -98 -67 -33 -35 65 45 169 129
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.02 0.03 0.04 0.08 0.07 0.05 0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 47 51 63 108 165 208 240 311 335 385 325
Debt-free Net Working Capital (DFNWC)		 264 261 280 449 476 484 492 443 477 900 877
Net Working Capital (NWC)		 264 261 280 449 476 484 492 443 477 900 877
Net Nonoperating Expense (NNE)		 5.68 4.22 2.38 7.42 4.12 2.92 3.58 52 2.76 14 8.70
Net Nonoperating Obligations (NNO)		 -117 -110 -116 -98 -67 -33 -35 65 45 169 129
Total Depreciation and Amortization (D&A)		 -0.80 -0.95 -1.09 -1.34 -1.33 -0.98 -0.92 -0.42 -0.01 -0.00 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 19.99% 17.67% 18.24% 40.75% 50.05% 53.85% 52.90% 58.54% - 55.03% 40.64%
Debt-free Net Working Capital to Revenue		 113.08% 90.17% 80.90% 169.55% 144.58% 125.34% 108.37% 83.28% - 128.49% 109.71%
Net Working Capital to Revenue		 113.08% 90.17% 80.90% 169.55% 144.58% 125.34% 108.37% 83.28% - 128.49% 109.71%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.09) ($0.07) $0.05 $0.03 $0.15 $0.03 $0.19 $2.69 $0.19 $0.14 $0.05
Adjusted Weighted Average Basic Shares Outstanding		 141.96M 146.21M 144.73M 145.10M 145.32M 146.68M 146.74M 145.42M 144.32M 144.44M 141.77M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.04 $0.02 $0.00 $0.03 $0.17 $2.43 $0.14 $0.12 $0.05
Adjusted Weighted Average Diluted Shares Outstanding		 148.51M 154.54M 159.42M 160.71M 160.34M 162.77M 162.56M 161.00M 161.41M 160.06M 157.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 154.42M 154.54M 154.82M 155.67M 157.07M 158.76M 158.67M 158.76M 159.69M 153.08M 153.07M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.74 -6.49 6.17 11 27 7.98 32 21 26 34 16
Normalized NOPAT Margin		 -19.88% -10.22% 8.40% 13.48% 25.38% 6.60% 22.50% 12.71% - 16.49% 6.86%
Pre Tax Income Margin		 -31.90% -16.82% 8.92% 5.09% 23.53% 4.52% 21.91% 16.02% - 9.94% 4.26%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.77 -3.67 2.65 1.39 4.67 1.81 5.60 4.85 - 2.21 1.62
NOPAT to Interest Expense		 -3.60 -2.84 2.33 1.04 3.96 1.18 4.73 65.92 - 2.01 0.99
EBIT Less CapEx to Interest Expense		 -4.77 -3.67 2.65 1.39 4.67 1.81 5.60 4.84 - 2.21 1.60
NOPAT Less CapEx to Interest Expense		 -3.60 -2.84 2.33 1.04 3.96 1.18 4.72 65.91 - 2.01 0.98
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 37.46% 38.02% 35.99% 21.87% - 40.08% 40.37%

Financials Breakdown Chart

Key Financial Trends

TG Therapeutics (NASDAQ:TGTX) has undergone a significant commercial ramp. Revenue increased from less than $1 million in the third quarter of 2022 to $240.3 million in Q2 2026. The latest quarter represented a 17.3% increase from Q1 2026 and a 70.1% increase from Q2 2025. Gross profit also rose to $199.1 million, although the gross margin eased slightly to approximately 82.9% from 83.6% in Q1.

Profitability remains positive but has moderated recently. Operating income declined from $34.8 million in Q1 2026 to $21.7 million in Q2, while net income fell from $19.8 million to $7.8 million. Higher research and development spending was the primary contributor: R&D expense nearly doubled sequentially to $95.3 million, while selling, general and administrative expense was $82.1 million. Interest expense of $16.6 million further reduced pretax earnings.

Cash generation improved during the latest quarter, with operating cash flow turning positive at $39.3 million compared with a $17.9 million outflow in Q1 2026. However, the balance sheet reflects a major increase in leverage. Cash and equivalents totaled $482.6 million, with total cash and investments of approximately $616.7 million, while long-term debt stood at $745.4 million. The company also reported $401.6 million of accounts receivable and $148.0 million of inventory, making working-capital management an important factor for investors.

  • Strong revenue momentum: Quarterly revenue has risen consistently from $63.5 million in Q1 2024 to $240.3 million in Q2 2026, indicating substantial commercial growth.
  • Positive operating profitability: TG Therapeutics has reported positive operating income in each of the provided quarters since Q2 2024, including $21.7 million in Q2 2026.
  • Improving operating cash flow: Operating cash flow improved by $57.2 million sequentially, moving from a $17.9 million outflow in Q1 2026 to a $39.3 million inflow in Q2.
  • Stronger equity position: Total equity increased to $604.1 million in Q2 2026 from $237.3 million in Q1 2024, supported by retained earnings improvements and equity financing activity.
  • Share count has generally declined: Basic weighted-average shares fell to 141.8 million in Q2 2026 from 146.7 million in Q2 2025, helped by common-stock repurchases.
  • Large liquid-asset base: Cash, short-term investments and long-term investments totaled approximately $616.7 million at quarter-end, but this amount was below the company’s $745.4 million of long-term debt.
  • Working-capital balances are elevated: Accounts receivable and inventory were $401.6 million and $148.0 million, respectively. These assets can support growth, but their conversion into cash should be monitored.
  • Profitability weakened sequentially: Net income declined 60.7% from Q1 2026 to $7.8 million, and diluted EPS dropped from $0.12 to $0.05.
  • R&D spending surged: Research and development expense increased from $48.4 million in Q1 2026 to $95.3 million in Q2, putting pressure on operating margins despite higher revenue.
  • Leverage rose sharply: Long-term debt increased from $245.3 million in Q3 2025 to approximately $745.4 million in Q2 2026. Interest expense also reached $16.6 million in the latest quarter, creating greater financial pressure if growth slows.

Overall, the statements show a company with accelerating revenue and a recent return to positive operating cash flow, but investors should balance that progress against rising debt, increasing development costs and a recent decline in earnings. The unusually large tax benefit recorded in Q3 2025 also makes year-over-year net-income comparisons less representative.

09/12/26 11:50 AM ETAI Generated. May Contain Errors.

TG Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, TG Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

TG Therapeutics' net income appears to be on a downward trend, with a most recent value of $447.18 million in 2025, falling from -$62.95 million in 2015. The previous period was $23.38 million in 2024. See where experts think TG Therapeutics is headed by visiting TG Therapeutics' forecast page.

TG Therapeutics' total operating income in 2025 was $123.32 million, based on the following breakdown:
  • Total Gross Profit: $515.57 million
  • Total Operating Expenses: $392.25 million

Over the last 10 years, TG Therapeutics' total revenue changed from $152.38 thousand in 2015 to $616.29 million in 2025, a change of 404,338.2%.

TG Therapeutics' total liabilities were at $415.23 million at the end of 2025, a 16.9% increase from 2024, and a 3,389.4% increase since 2015.

In the past 10 years, TG Therapeutics' cash and equivalents has ranged from $25.03 million in 2016 to $553.44 million in 2020, and is currently $79.15 million as of their latest financial filing in 2025.

Over the last 10 years, TG Therapeutics' book value per share changed from 1.93 in 2015 to 4.08 in 2025, a change of 111.1%.


Related Companies

Financial statements for NASDAQ:TGTX last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly
The biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...
Investors Alley | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The retirement income that answers “yes” when everything else says no
Todd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...
Eagle Publishing | Sponsoredtc pixel
My ‘one day’ retirement secret
TradeSmith's AI research team, backed by a $17 million investment and led by a former NSA codebreaker, built a...
TradeSmith | Sponsoredtc pixel
17 Nobel Prize winners… one startling warning
On July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...
Porter & Company | Sponsoredtc pixel
your job is on the list
The CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...
Behind the Markets | Sponsoredtc pixel